Global Varicella Live Vaccine Market Research Report 2022
Varicella zoster is also known as Human alphaherpesvirus 3 and causes chicken pox and herpes zoster in humans. The infection caused by this virus can be prevented by the use of vaccinations that are specially formulated to provide immunity against the virus. There are mainly two types of vaccinations available to provide immunity against varicella zoster such as monovalent varicella vaccine and combination varicella vaccine.
Due to the COVID-19 pandemic, the global Varicella Live Vaccine market size is estimated to be worth US$ 2370.2 million in 2021 and is forecast to a readjusted size of US$ 3051.8 million by 2028 with a CAGR of 3.2% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Varicella Live Vaccine market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Varicella Live Vaccine landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Monovalent Varicella Vaccine accounting for % of the Varicella Live Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Chickenpox Immunization segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Varicella Live Vaccine include Bio-Med Pvt. Limited, Changchun BCHT Biotechnology, Emcure Pharmaceuticals, GlaxoSmithKline, GC Pharma, Merck & Co. Inc., Mitsubishi Tanabe Pharma, Novo Medi Sciences and Sanofi and etc. In terms of revenue, the global 3 largest players have a % market share of Varicella Live Vaccine in 2021.
This report focuses on Varicella Live Vaccine volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Varicella Live Vaccine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Varicella Live Vaccine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Monovalent Varicella Vaccine
Combination Varicella Vaccine
Segment by Application
Chickenpox Immunization
Herpes Zoster Immunization
Measles, Mumps, Rubella and Varicella (MMRV) Immunization
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Bio-Med Pvt. Limited
Changchun BCHT Biotechnology
Emcure Pharmaceuticals
GlaxoSmithKline
GC Pharma
Merck & Co. Inc.
Mitsubishi Tanabe Pharma
Novo Medi Sciences
Sanofi
Takeda Pharmaceutical Company Limited.
Due to the COVID-19 pandemic, the global Varicella Live Vaccine market size is estimated to be worth US$ 2370.2 million in 2021 and is forecast to a readjusted size of US$ 3051.8 million by 2028 with a CAGR of 3.2% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Varicella Live Vaccine market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Varicella Live Vaccine landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Monovalent Varicella Vaccine accounting for % of the Varicella Live Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Chickenpox Immunization segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Varicella Live Vaccine include Bio-Med Pvt. Limited, Changchun BCHT Biotechnology, Emcure Pharmaceuticals, GlaxoSmithKline, GC Pharma, Merck & Co. Inc., Mitsubishi Tanabe Pharma, Novo Medi Sciences and Sanofi and etc. In terms of revenue, the global 3 largest players have a % market share of Varicella Live Vaccine in 2021.
This report focuses on Varicella Live Vaccine volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Varicella Live Vaccine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Varicella Live Vaccine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Monovalent Varicella Vaccine
Combination Varicella Vaccine
Segment by Application
Chickenpox Immunization
Herpes Zoster Immunization
Measles, Mumps, Rubella and Varicella (MMRV) Immunization
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Bio-Med Pvt. Limited
Changchun BCHT Biotechnology
Emcure Pharmaceuticals
GlaxoSmithKline
GC Pharma
Merck & Co. Inc.
Mitsubishi Tanabe Pharma
Novo Medi Sciences
Sanofi
Takeda Pharmaceutical Company Limited.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
